PeRsOnaliSed care Planning for oldER people with frailty (PROSPER): protocol for a randomised controlled trial.

Frailty Older people Personalised-Care-Planning Quality of life RCT eFI

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
02 Jan 2024
Historique:
received: 27 10 2023
accepted: 06 12 2023
medline: 4 1 2024
pubmed: 4 1 2024
entrez: 3 1 2024
Statut: epublish

Résumé

Frailty is common in older age and is characterised by loss of biological reserves across multiple organ systems. These changes associated with frailty mean older people can be vulnerable to sudden, dramatic changes in health because of relatively small problems. Older people with frailty are at increased risk of adverse outcomes including disability, hospitalisation, and care home admission, with associated reduction in quality of life and increased NHS and social care costs. Personalised Care Planning offers an anticipatory, preventative approach to supporting older adults to live independently for longer, but it has not been robustly evaluated in a population of older adults with frailty. Following an initial feasibility study, this multi-centre, individually randomised controlled trial aims to establish whether personalised care planning for older people improves health-related quality of life. It will recruit 1337 participants from general practices across Yorkshire and Humber and Mid-Mersey in the North of England. Eligible patients will be aged 65 and over with an electronic frailty index score of 0.21 or above, living in their own homes, without severe cognitive impairment and not in receipt of end-of-life care. Following confirmation of eligibility, informed consent and baseline data collection, participants will be individually randomised to the PeRsOnaliSed care Planning for oldER people with frailty (PROSPER) intervention or usual care in a 2.6:1 allocation ratio. Participants will not be blinded to allocation, but data collection and analysis will be blinded. The intervention will be delivered over 12 weeks by a Personal Independence Co-ordinator worker based within a voluntary sector organisation, Age UK. The primary outcomes are health-related quality of life, measured using both the physical and mental components of the Short-Form 12 Item Health Questionnaire at 12 months after randomisation. Secondary outcomes comprise activities of daily living, self-management capabilities and loneliness, admission to care homes, hospitalisations, and health and social care resource use at 12 months post randomisation. Parallel cost-effectiveness and process evaluations will be conducted alongside the trial. The PROSPER study will evaluate the effectiveness and cost-effectiveness of a personalised care planning approach for older people with frailty and inform the process of its implementation. ISRCTN16123291 .  Registered on  28 August 2020.

Sections du résumé

BACKGROUND BACKGROUND
Frailty is common in older age and is characterised by loss of biological reserves across multiple organ systems. These changes associated with frailty mean older people can be vulnerable to sudden, dramatic changes in health because of relatively small problems. Older people with frailty are at increased risk of adverse outcomes including disability, hospitalisation, and care home admission, with associated reduction in quality of life and increased NHS and social care costs. Personalised Care Planning offers an anticipatory, preventative approach to supporting older adults to live independently for longer, but it has not been robustly evaluated in a population of older adults with frailty.
METHODS METHODS
Following an initial feasibility study, this multi-centre, individually randomised controlled trial aims to establish whether personalised care planning for older people improves health-related quality of life. It will recruit 1337 participants from general practices across Yorkshire and Humber and Mid-Mersey in the North of England. Eligible patients will be aged 65 and over with an electronic frailty index score of 0.21 or above, living in their own homes, without severe cognitive impairment and not in receipt of end-of-life care. Following confirmation of eligibility, informed consent and baseline data collection, participants will be individually randomised to the PeRsOnaliSed care Planning for oldER people with frailty (PROSPER) intervention or usual care in a 2.6:1 allocation ratio. Participants will not be blinded to allocation, but data collection and analysis will be blinded. The intervention will be delivered over 12 weeks by a Personal Independence Co-ordinator worker based within a voluntary sector organisation, Age UK. The primary outcomes are health-related quality of life, measured using both the physical and mental components of the Short-Form 12 Item Health Questionnaire at 12 months after randomisation. Secondary outcomes comprise activities of daily living, self-management capabilities and loneliness, admission to care homes, hospitalisations, and health and social care resource use at 12 months post randomisation. Parallel cost-effectiveness and process evaluations will be conducted alongside the trial.
DISCUSSION CONCLUSIONS
The PROSPER study will evaluate the effectiveness and cost-effectiveness of a personalised care planning approach for older people with frailty and inform the process of its implementation.
TRIAL REGISTRATION BACKGROUND
ISRCTN16123291 .  Registered on  28 August 2020.

Identifiants

pubmed: 38167481
doi: 10.1186/s13063-023-07857-1
pii: 10.1186/s13063-023-07857-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8

Subventions

Organisme : Programme Grants for Applied Research
ID : RP-PG-0216-20003

Informations de copyright

© 2023. The Author(s).

Références

Rockwood K, Mitnitski A, Song X, Steen B, Skoog I. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc. 2006;54(6):975–9.
doi: 10.1111/j.1532-5415.2006.00738.x pubmed: 16776795
Mangin D, Heath I, Jamoulle M. Beyond diagnosis: rising to the multimorbidity challenge. BMJ. 2012;344:e3526.
doi: 10.1136/bmj.e3526 pubmed: 22695898
Coulter AEV, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care planning for adults with chronic or long-term health conditions. Cochrane Database Syst Rev. 2015;3.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–62.
doi: 10.1016/S0140-6736(12)62167-9 pubmed: 23395245
Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84(2):191–215.
doi: 10.1037/0033-295X.84.2.191 pubmed: 847061
Bandura A. Health Promotion fron the perspective of social cognitive theory. Psychol Health. 1998;13(4):623–49.
doi: 10.1080/08870449808407422
Bower PRD, Roland M, Blakeman T, Protheroe J, Rogers A, Kennedy A, Sibbald B, Richardson G. Care planning in the treatment of long-term conditions: final report of the CAPITOL project. DH London; 2013.
Reeves DHM, Rick J, Rowe K, Small N, Burt J, Roland M, Protheroe J, Blakeman T, Richardson G, Kennedy A, Bower P. Care plans and care planning in the management of long-term conditions in the UK: a controlled prospective cohort study. Br J Gen Pract : J Royal Coll Gen Pract. 2012;64(626):568–75.
doi: 10.3399/bjgp14X681385
NHS England. The NHS Long Term Plan www.longtermplan.nhs.uk2019 [Available from: www.longtermplan.nhs.uk .
Y F. Blended evaluation of Phase 2 of the Age UK Personalised Integrated Care Programme. 2018.
Heaven A, Bower P, Cundill B, Farrin A, Foster M, Foy R, et al. Study protocol for a cluster randomised controlled feasibility trial evaluating personalised care planning for older people with frailty: PROSPER V2 27/11/18. Pilot Feasibility Stud. 2020;6:56.
doi: 10.1186/s40814-020-00598-x pubmed: 32355566 pmcid: 7187486
England PH. https://fingertips.phe.org.uk/ .
Nikolova S, Heaven A, Hulme C, West R, Pendleton N, Humphrey S, et al. Social care costs for community-dwelling older people living with frailty. Health Soc Care Community. 2022;30(3):e804-ee11.
doi: 10.1111/hsc.13450 pubmed: 34080751
Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45(3):353–60.
doi: 10.1093/ageing/afw039 pubmed: 26944937 pmcid: 4846793
Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, et al. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. Jama. 2022;328(22):2252–64.
doi: 10.1001/jama.2022.21022 pubmed: 36511921
Department of Health. Mental Capacity Act. HMSO; 2005.
Ahmed S, Heaven A, Lawton R, Rawlings G, Sloan C, Clegg A. Behaviour change techniques in personalised care planning for older people: a systematic review. Br J Gen Pract : J Royal Coll Gen Pract. 2021;71(703):e121-e1e7.
Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ : Br Med J. 2014;348:g1687.
Smelt AF van der Weele GM Blom JW Gussekloo J Assendelft WJ. How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract : J Royal Coll Gen Pract. 2010;60(576):e305–18.
Dawson L, Zarin DA, Emanuel EJ, Friedman LM, Chaudhari B, Goodman SN. Considering usual medical care in clinical trial design. PLoS Med. 2009;6(9):e1000111.
doi: 10.1371/journal.pmed.1000111 pubmed: 19787044 pmcid: 2746285
Walters SJ, Munro JF, Brazier JE. Using the SF-36 with older adults: a cross-sectional community-based survey. Age Ageing. 2001;30(4):337–43.
doi: 10.1093/ageing/30.4.337 pubmed: 11509313
Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheumatism. 2001;45(4):384–91.
doi: 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0 pubmed: 11501727
Roberts C, Roberts SA. Design and analysis of clinical trials with clustering effects due to treatment. Clin Trials (London, England). 2005;2(2):152–62.
doi: 10.1191/1740774505cn076oa
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.
doi: 10.1016/S0167-6296(01)00130-8 pubmed: 11939242
National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013 [Internet]. London: National Institute for Health and Care Excellence (NICE); 2013. Process and Methods Guides No. 9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395867/ .
Briggs ACK, Sculpher M. Decision modelling for health economic evaluation. Oxford: OUP; 2006.
doi: 10.1093/oso/9780198526629.001.0001
Edlin RMC, Hulme C, Hall P, Wright J. Cost-effectiveness modelling for health technology assessment. London: ADIS; 2015.
doi: 10.1007/978-3-319-15744-3
Kime N, Heaven A, Quinn C, Brown S. OP79 Optimising patient and public engagement in trials of complex interventions. J Epidemiol Community Health. 2020;74(Suppl 1):A37-A.

Auteurs

Anne Heaven (A)

Academic Unit for Ageing and Stroke Research, University of Leeds, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK. anne.heaven@bthft.nhs.uk.
Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds, LS2 9JT, UK. anne.heaven@bthft.nhs.uk.

Peter Bower (P)

NIHR Older People and Frailty Policy Research Unit, Centre for Primary Care and Health Services Research, Manchester Academic Health Science Centre, University of Manchester, M13 9PL, Manchester, UK.

Florence Day (F)

Leeds Institute of Clinical Trials Research (LICTR), Clinical Trials Research Unit, University of Leeds, Leeds, LS2 9JT, UK.

Amanda Farrin (A)

Leeds Institute of Clinical Trials Research (LICTR), Clinical Trials Research Unit, University of Leeds, Leeds, LS2 9JT, UK.

Catherine Fernadez (C)

Leeds Institute of Clinical Trials Research (LICTR), Clinical Trials Research Unit, University of Leeds, Leeds, LS2 9JT, UK.

Marilyn Foster (M)

PPI Representative, c/o Academic Unit for Ageing and Stroke Research, University of Leeds, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK.

Robbie Foy (R)

Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds, LS2 9JT, UK.

Rebecca Hawkins (R)

Academic Unit for Ageing and Stroke Research, University of Leeds, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK.
Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds, LS2 9JT, UK.

Claire Hulme (C)

Health Economics Group, Institute of Health Research, University of Exeter, Exeter, EX1 2LU, UK.

Sara Humphrey (S)

OPMH & Dementia at Yorkshire and Humber Clinical Network, Rotherham, UK.

Rebecca Lawton (R)

School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.

Catriona Parker (C)

Cancer Clinical Trial Centre, Weston Park Cancer Centre, Whitham Road, Sheffield, S10 2SJ, UK.

Ellen Thompson (E)

Leeds Institute of Clinical Trials Research (LICTR), Clinical Trials Research Unit, University of Leeds, Leeds, LS2 9JT, UK.

Robert West (R)

Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds, LS2 9JT, UK.

Andrew Clegg (A)

Academic Unit for Ageing and Stroke Research, University of Leeds, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK.
Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds, LS2 9JT, UK.

Classifications MeSH